Weiss Asset Management LP's Form 4 filing
Avadel Pharmaceuticals PLC (AVDL) · filed Feb 18, 2026
- Accession no.
- 0001357550-26-000015
- Filed
- Feb 18, 2026, 5:18 PM ET
- Trade date
- Feb 13, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $233.4M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Weiss Asset Management LPCIK 0001357550 | Other: Former 10% Owner |
| Weiss Andrew MCIK 0001357643 | Other: Former 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | Ordinary Shares | SSaleDisposed | −11,112,052 | $21.00F1 | −$233,353,092 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the cash portion of the consideration paid to shareholders upon the closing of the acquisition of the Issuer by Alkermes plc. In connection with such transaction, each outstanding share was automatically converted into the right to receive $21.00 per share in cash, plus a contingent value right to receive a payment of $1.50 in cash if a specified milestone is achieved.
Referenced by the price of 1 transaction in Table I.